Cigna Group Past Earnings Performance
Past criteria checks 4/6
Cigna Group's earnings have been declining at an average annual rate of -9.5%, while the Healthcare industry saw earnings growing at 4% annually. Revenues have been growing at an average rate of 11.7% per year. Cigna Group's return on equity is 15.9%, and it has net margins of 2.3%.
Key information
-9.51%
Earnings growth rate
-2.82%
EPS growth rate
| Healthcare Industry Growth | 8.50% |
| Revenue growth rate | 11.70% |
| Return on equity | 15.88% |
| Net Margin | 2.26% |
| Next Earnings Update | 30 Jul 2026 |
Recent past performance updates
Recent updates
Seeking Alpha • May 18
Cigna: Shares Marching To Full Recovery
Summary Cigna Group is reiterated as a "Buy," driven by strong Q1 2026 results, raised guidance, and sustained business momentum. CI’s pharmacy and behavioral health segments are fueling revenue growth, while divestitures and PBM reform temporarily temper 2026 earnings. Shares trade at a 25% discount to a $377 fair value estimate, offering potential 15% annual total returns through 2031. Cigna’s robust balance sheet, market-leading dividend coverage, and growth catalysts in biosimilars and behavioral health underpin the investment thesis. Read the full article on Seeking AlphaAnalysis Article • May 04
The The Cigna Group (NYSE:CI) First-Quarter Results Are Out And Analysts Have Published New Forecasts
The Cigna Group ( NYSE:CI ) came out with its first-quarter results last week, and we wanted to see how the business is...
Narrative Update • May 02
CI: Leadership Transition And Buybacks Will Support Future Share Upside
Analysts have increased their price target on Cigna Group by about $1. This reflects small adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions in their models.Narrative Update • Apr 17
CI: Leadership Transition And Buybacks Will Drive Future Upside
Analysts have trimmed their average price target on Cigna Group by about $0.38 to roughly $338.42, reflecting small updates to fair value estimates, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Cigna Group plans a leadership transition, with current CEO David M.Narrative Update • Apr 02
CI: Leadership Transition And Onsite Care Expansion Will Drive Future Upside
Analysts have slightly refined their view on Cigna Group, trimming the price target by a fraction to $338.79 as updated assumptions for revenue growth, profit margins, and future P/E bring the model into closer alignment with their latest expectations. What's in the News Cigna Group plans a leadership transition, with David M.Narrative Update • Mar 19
CI: Onsite Care Expansion And Leadership Transition Will Support Future Upside
Analysts have nudged their fair value estimate for Cigna Group from about $336.67 to roughly $338.80. This reflects updated views on revenue growth, profit margins, and an anticipated forward P/E of around 13.43x.Narrative Update • Mar 05
CI: Onsite Care Expansion Will Support Future Upside Potential
Analysts now set Cigna Group's fair value estimate at about $336.67, up from roughly $332.62, reflecting updated assumptions that incorporate slightly higher revenue growth, profit margins, and a lower future P/E multiple. What's in the News Cigna Group plans a leadership transition, with CEO David M.Narrative Update • Feb 19
CI: Higher Margin Outlook And Onsite Care Expansion Will Support Upside
Analysts have modestly lifted their price target on Cigna Group to $332.62 from $326.92, citing updated assumptions that combine slightly lower revenue growth with a higher profit margin and a future P/E of 15.62. What's in the News A class action lawsuit has been filed against Express Scripts, Cigna, and Evernorth, alleging a rebate diversion scheme that used an offshore entity, Ascent, to collect billions of dollars in kickbacks labeled as fees instead of passing rebates through to pharmacy benefit management clients, including the Plumbers' Welfare Fund.Narrative Update • Feb 04
CI: Onsite Clinic And Stable Assumptions Will Support Future Upside
Analysts have kept their price target for The Cigna Group broadly unchanged at about US$327, citing only slight adjustments to revenue growth, profit margin and future P/E assumptions rather than any major shift in their outlook. What's in the News Hankook Tire America Corp.Narrative Update • Jan 21
CI: Completed Buybacks And New Employee Clinic Will Support Future Upside
Analysts have nudged their fair value estimate for Cigna Group slightly higher to US$326.92 from US$325.57, citing minor refinements to discount rate assumptions, revenue growth expectations, profit margin inputs, and the forward P/E multiple used in their models. What's in the News Hankook Tire America Corp.Narrative Update • Jan 07
CI: Massive Share Buyback And Clinic Expansion Will Support Future Earnings Upside
Analysts have slightly reduced their price target for Cigna Group, trimming fair value by about $0.69 to $325.57 as they factor in a more moderate revenue growth outlook, along with a small improvement in expected profit margins and future P/E assumptions. What's in the News Hankook Tire America Corp.Narrative Update • Dec 15
CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum
Narrative Update on Cigna Group Analysts have slightly lowered their price target on Cigna Group by approximately $2 to around $326 per share, reflecting modest tweaks to assumptions on long term growth, profitability, and valuation multiples, while maintaining a broadly constructive outlook. What's in the News Cigna Group reported that between July 1 and September 30, 2025, it repurchased no additional shares under its existing authorization, having already completed the buyback of about 133.5 million shares, or 41.09% of shares outstanding, for roughly $34.44 billion since the program was announced in December 2018 (company filing).Narrative Update • Nov 30
CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum
Analysts have raised their price target for Cigna Group to $328.35 per share, citing moderate adjustments to key financial metrics. These include a higher projected future price-to-earnings ratio and continued expectations for growth and profitability.Narrative Update • Nov 16
CI: Significant Buybacks And 2026 Guidance Will Drive Upside Momentum
Narrative Update on Cigna Group Analysts have lowered their price target for Cigna Group from $349.04 to $328.35. This change reflects adjustments for a slightly higher discount rate as well as revised expectations for revenue growth and profit margins.Narrative Update • Nov 01
CI: Share Repurchase Momentum Will Drive Long-Term Shareholder Value Creation
Analysts have lowered their price target for Cigna Group from $369.13 to $349.04. This change reflects updated expectations around modestly higher revenue growth, which are offset by a slight dip in profit margin projections.Analysis Article • Jul 10
The Cigna Group (NYSE:CI) Screens Well But There Might Be A Catch
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Analysis Article • Jun 19
These 4 Measures Indicate That Cigna Group (NYSE:CI) Is Using Debt Reasonably Well
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Mar 31
The Cigna Group: Compelling Exposure To Diversified Healthcare At A Discount Price
Summary Cigna is positioned to benefit from utilization normalization and aims for 10%-14% annual EPS growth by reducing Medicare exposure and improving Commercial business. Despite industry challenges, Cigna achieved 8%-9% YoY EPS growth in 2023-2024, demonstrating strong cost discipline and effective management. The sale of Cigna's Medicare unit and focus on lower-cost biosimilars and streamlined care accessibility are key strategic moves for future growth. With an attractive valuation and minimal downside risk, Cigna stock is rated a BUY, offering at least 33% upside potential even in bearish conditions. Read the full article on Seeking AlphaSeeking Alpha • Feb 17
Cigna Is A Buy: Market Overreaction Creates A Big Opportunity
Summary Cigna looks undervalued at under 10x earnings, with strong growth potential. Evernorth continues to expand, adding to the company’s long-term value. Large stock buybacks are supporting earnings per share and investor returns. Regulatory risks, rising costs, and competition remain challenges to watch. If Cigna meets its targets, the stock could rise 20-30% from here. Read the full article on Seeking AlphaSeeking Alpha • Jan 18
Cigna: Buy The Drop On This Undervalued Growth Stock
Summary Cigna's current valuation presents a compelling opportunity, trading at a forward PE of 9.9, significantly below its historical average of 12.0x. The company carries diversified revenue streams and consistent earnings growth, with Healthcare and Evernorth divisions driving strong performance and a 13% EPS CAGR over 10 years. Management targets 10-14% long-term annual EPS growth, supported by increased biosimilar adoption, behavioral health services growth, and aggressive share buybacks. CI's growing dividend and robust fundamentals make it an attractive choice for value and growth investors, despite potential regulatory and macroeconomic risks. Read the full article on Seeking AlphaSeeking Alpha • Dec 13
Cigna And The Risk Of PBMs - I'm Staying Out Above $230/Share
Summary Cigna faces significant risks due to potential healthcare reforms and scrutiny on PBMs, making it a "Hold" until it drops below $230/share. The US healthcare system's high costs and structural issues contribute to the uncertainty surrounding Cigna's long-term profitability and business model. Despite strong historical performance, the potential breakup of PBMs and legislative changes could drastically impact Cigna's future earnings and growth. The current valuation does not justify investment; Cigna's appeal lies in its fundamental strengths but is overshadowed by systemic risks and political uncertainties. Read the full article on Seeking AlphaSeeking Alpha • Sep 26
Cigna: This Dividend Grower Could Be Worth Buying Now
Summary The managed care company's total revenue and non-GAAP EPS climbed higher in the second quarter. Cigna's dividend is comfortably covered by non-GAAP EPS and free cash flow. Shares of the stock appear to be priced at a 17% discount to fair value. Cigna could be set up to generate strong total returns in the next couple of years. Read the full article on Seeking AlphaSeeking Alpha • Sep 19
Cigna: Growth From Specialty Pharmacy And Care; Initiate With 'Buy'
Summary I am initiating a 'Buy' rating for Cigna with a one-year target price of $450 per share, driven by strong Specialty and Cigna Healthcare growth. Cigna's Specialty Pharmacy and Care Market, accounting for 30% of revenue, is poised for above-market growth due to its leadership in the chronic market and biosimilar offerings. Cigna Healthcare's divestiture of low-margin Medicare businesses will allow focus on employer-sponsored plans, targeting small and mid-size enterprises, contributing to 7% organic revenue growth. Despite low operating margins and elevated cost trends, Cigna's share repurchase program and SG&A optimization are expected to support future margin expansion and free cash flow growth. Read the full article on Seeking AlphaSeeking Alpha • Jul 29
Cigna Group: Services Focus Leads To Outperformance
Summary Cigna Group's medical memberships are focused on "services-only" commercial memberships. The fee-based rather than risk-based nature of these memberships makes Cigna more resilient to rising medical costs. The Evernorth segment should see high-single-digit growth for the foreseeable future, driven by Healthcare Services and specialty pharmacy Accredo. The low valuation coupled with the mid-single-digit earnings growth outlook makes Cigna stock attractive at current prices. Read the full article on Seeking AlphaSeeking Alpha • Jul 12
Cigna: Game Over For PBMs?
Summary Pharmacy Benefit Managers are increasingly in the spotlight of regulators and the media, potentially leading to government intervention. Express Scripts, Cigna's PBM, is responsible for nearly 75% of the company's revenue, which raises the question of whether CI stock is still a safe investment. This article discusses the potential implications in a scenario-based approach, focusing on segment profit, consolidated profit, dividend safety, and valuation. In addition, I share my thoughts on the recent opioid litigation in Arkansas and explain why I continue to sleep well with my investment in Cigna. Read the full article on Seeking AlphaRevenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Cigna Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 277,892 | 6,288 | 12,087 | 0 |
| 31 Dec 25 | 274,900 | 5,957 | 13,558 | 0 |
| 30 Sep 25 | 268,077 | 6,147 | 13,929 | 0 |
| 30 Jun 25 | 262,023 | 5,018 | 14,350 | 0 |
| 31 Mar 25 | 255,368 | 5,034 | 14,700 | 0 |
| 31 Dec 24 | 247,121 | 3,434 | 14,569 | 0 |
| 30 Sep 24 | 232,586 | 3,039 | 14,552 | 0 |
| 30 Jun 24 | 217,940 | 3,708 | 14,624 | 0 |
| 31 Mar 24 | 206,003 | 3,620 | 14,442 | 0 |
| 31 Dec 23 | 195,265 | 5,164 | 14,324 | 0 |
| 30 Sep 23 | 189,904 | 5,328 | 14,050 | 0 |
| 30 Jun 23 | 186,137 | 6,677 | 13,609 | 0 |
| 31 Mar 23 | 183,029 | 6,774 | 13,421 | 0 |
| 31 Dec 22 | 180,518 | 6,704 | 13,045 | 0 |
| 30 Sep 22 | 180,453 | 6,627 | 13,042 | 0 |
| 30 Jun 22 | 179,460 | 5,491 | 12,999 | 0 |
| 31 Mar 22 | 177,113 | 5,401 | 12,748 | 0 |
| 31 Dec 21 | 174,069 | 5,370 | 12,791 | 0 |
| 30 Sep 21 | 170,102 | 8,384 | 13,195 | 0 |
| 30 Jun 21 | 166,769 | 8,151 | 13,402 | 0 |
| 31 Mar 21 | 162,903 | 8,438 | 13,697 | 0 |
| 31 Dec 20 | 160,401 | 8,458 | 13,660 | 0 |
| 30 Sep 20 | 156,934 | 5,300 | 13,484 | 0 |
| 30 Jun 20 | 154,535 | 5,263 | 13,521 | 0 |
| 31 Mar 20 | 154,089 | 4,917 | 13,386 | 0 |
| 31 Dec 19 | 153,566 | 5,104 | 13,315 | 0 |
| 30 Sep 19 | 129,621 | 4,271 | 12,479 | 0 |
| 30 Jun 19 | 102,522 | 3,692 | 12,196 | 0 |
| 31 Mar 19 | 75,183 | 3,090 | 11,739 | 0 |
| 31 Dec 18 | 48,650 | 2,637 | 11,230 | 0 |
| 30 Sep 18 | 44,768 | 2,759 | 18,405 | 0 |
| 30 Jun 18 | 43,800 | 2,547 | 15,343 | 0 |
| 31 Mar 18 | 42,745 | 2,554 | 12,640 | 0 |
| 31 Dec 17 | 41,806 | 2,237 | 9,846 | 0 |
| 30 Sep 17 | 41,332 | 2,353 | 82 | 0 |
| 30 Jun 17 | 40,723 | 2,249 | 82 | 0 |
| 31 Mar 17 | 40,258 | 1,946 | 82 | 0 |
| 31 Dec 16 | 39,838 | 1,867 | 9,626 | 0 |
| 30 Sep 16 | 39,252 | 1,911 | 92 | 0 |
| 30 Jun 16 | 38,761 | 2,002 | 92 | 0 |
| 31 Mar 16 | 38,293 | 2,080 | 92 | 0 |
| 31 Dec 15 | 37,876 | 2,094 | 92 | 0 |
| 30 Sep 15 | 37,276 | 2,135 | 0 | 0 |
| 30 Jun 15 | 36,644 | 2,122 | 0 | 0 |
Quality Earnings: CI has high quality earnings.
Growing Profit Margin: CI's current net profit margins (2.3%) are higher than last year (2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CI's earnings have declined by 9.5% per year over the past 5 years.
Accelerating Growth: CI's earnings growth over the past year (24.9%) exceeds its 5-year average (-9.5% per year).
Earnings vs Industry: CI earnings growth over the past year (24.9%) exceeded the Healthcare industry 17%.
Return on Equity
High ROE: CI's Return on Equity (15.9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/31 04:35 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
The Cigna Group is covered by 40 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Hua Ha | Baird |
| Joshua Raskin | Barclays |